secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANGOCEUTICALS, INC. (MGRX)
CIK:        0001938046
Form:       8-K
Filed at:   2026-07-30T11:00:26+00:00
Accession:  0001493152-26-035323
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mangoceuticals enters business combination with Nuclea Energy; Nuclea shareholders to own ~96% of combined entity
--------------------------------------------------------------------------------

- Nuclea shareholders will receive exchangeable shares exchangeable 1:1 for MGRX common, representing ~96% of fully diluted equity.
- Existing Mangoceuticals shareholders will hold approximately 4% of the combined company.
- Jacob Cohen to resign as CEO at closing, become President; Sagar Sanghera to become Executive Chairman, Josef Freundorfer CEO.
- Transaction requires minimum $15M PIPE financing, stockholder approval, and Nasdaq non-objection; closing expected before approvals.
- Bylaw amended to reduce quorum from majority to one-third of voting power.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1938046/000149315226035323/0001493152-26-035323-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1938046/000149315226035323/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-035323

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer